Schizophrenia – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)

Schizophrenia is a psychiatric disease that usually requires long-term treatment. The primary goals of treatment are to reduce the frequency and severity of psychotic episodes, maintain the reduction in these symptoms over the long term, and improve patients’ functional capacity. Schizophrenia is a highly drug-treated condition that uses an array of antipsychotic medications, including atypical and typical antipsychotic drugs, resulting in a complex treatment algorithm. Although the drug market is entrenched with generic therapies, the need for longer-acting, more-effective, and more-tolerable drugs gives branded agents (e.g., Janssen’s Invega Trinza, Intra-Cellular Therapies’ Caplyta, Indivior’s Perseris, AbbVie’s Vraylar) the opportunity to be incorporated into the treatment algorithm. As such, understanding the treatment dynamics, with the presence of both long-established and newer-to-market branded drugs, will be crucial for drug developers and marketers of in-line products to understand physicians’ prescribing behavior in schizophrenia.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed schizophrenia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed schizophrenia patients?
  • How have oral drugs (e.g., Caplyta, Rexulti, Vraylar) and long-acting injectable drugs (e.g., Abilify Maintena, Aristada, Invega Sustenna, Invega Trinza) been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of schizophrenia patients receive drug therapy within one year of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of schizophrenia patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Solution enhancement

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Geography: United States

Real world data: Longitudinal patient-level claims data analysis

Key companies: AbbVie, Alkermes, Janssen, Indivior, Intra-Cellular Therapies, Lundbeck, Otsuka, Sumitomo Dainippon Pharma / Sunovion Pharmaceuticals, Noven Pharma

Key drugs covered: Invega Sustenna, Invega Trinza, Abilify Maintena, Aristada, Risperdal Consta, Latuda, Rexulti, Vraylar, Perseris, Caplyta, Secuado, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, typical antipsychotics, other generics

Key analysis provided

  • Brand / therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flowcharts

Table of contents

  • Schizophrenia - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
    • Treatment Algorithms CDA Schizophrenia US May 2022
    • Treatment Algorithms CDA Schizophrenia US 2022 Dashboard

launch Related Market Assessment Reports